CN1148341A - 口服阿来屈酯液体制剂 - Google Patents
口服阿来屈酯液体制剂 Download PDFInfo
- Publication number
- CN1148341A CN1148341A CN95193086A CN95193086A CN1148341A CN 1148341 A CN1148341 A CN 1148341A CN 95193086 A CN95193086 A CN 95193086A CN 95193086 A CN95193086 A CN 95193086A CN 1148341 A CN1148341 A CN 1148341A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- alendronate
- liquid
- citric acid
- sodium citrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 229940062527 alendronate Drugs 0.000 title claims abstract description 48
- 239000012669 liquid formulation Substances 0.000 title abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 239000006188 syrup Substances 0.000 claims abstract description 9
- 235000020357 syrup Nutrition 0.000 claims abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 239000000872 buffer Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 239000001509 sodium citrate Substances 0.000 claims description 14
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 229930006000 Sucrose Natural products 0.000 claims description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000005720 sucrose Substances 0.000 claims description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000002738 chelating agent Substances 0.000 claims description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
- 210000000988 bone and bone Anatomy 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 235000010199 sorbic acid Nutrition 0.000 claims description 5
- 239000004334 sorbic acid Substances 0.000 claims description 5
- 229940075582 sorbic acid Drugs 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 208000032183 Scleromalacia Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000000857 drug effect Effects 0.000 claims description 4
- NTJPVVKEZMOHNU-UHFFFAOYSA-N 6-(oxan-4-yl)-1h-indazole Chemical compound C1COCCC1C1=CC=C(C=NN2)C2=C1 NTJPVVKEZMOHNU-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 3
- 235000019800 disodium phosphate Nutrition 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- 235000016337 monopotassium tartrate Nutrition 0.000 claims description 3
- 235000019321 monosodium tartrate Nutrition 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 claims description 3
- 229940086065 potassium hydrogentartrate Drugs 0.000 claims description 3
- 229940119126 sodium bitartrate Drugs 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- -1 antiseptic Substances 0.000 description 8
- 239000003086 colorant Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 208000006386 Bone Resorption Diseases 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 6
- 230000024279 bone resorption Effects 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 208000019505 Deglutition disease Diseases 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000004696 coordination complex Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 208000005368 osteomalacia Diseases 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- IZUPJOYPPLEPGM-UHFFFAOYSA-M sodium;hydron;phthalate Chemical compound [Na+].OC(=O)C1=CC=CC=C1C([O-])=O IZUPJOYPPLEPGM-UHFFFAOYSA-M 0.000 description 2
- PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- RNXTXSDKXTVVPK-UHFFFAOYSA-N NCCCC(O)=C(C(CC)(CC)P(O)(O)=O)CCCC Chemical compound NCCCC(O)=C(C(CC)(CC)P(O)(O)=O)CCCC RNXTXSDKXTVVPK-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 210000003275 diaphysis Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004079 mineral homeostasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
通过服用容易吞服的阿来屈酯液体制剂来治疗的预防难于吞咽的病人的骨损失症。还叙述了糖浆、水溶液、由用前冲调粉末得到的水溶液等阿来屈酯的药物剂型，用它们来进行治疗。
Description
发明领域
本发明一般涉及阿来屈酯的口服液体制剂，即4-氨基-1-羟基亚丁基-1，1-二膦酸一钠三水合物，用它来抑制吞咽困难病人的骨吸收。
发明背景
正常的骨骼是永恒地进行钙吸收及钙再沉积的活组织，其净效果保持着恒定的矿物质平衡。这种双向过程一般称之为“骨的滚动”。对于正常生长的骨骼，矿物质的沉积处于与矿物质吸收的平衡之中，而在某些病理条件下，骨吸收超过了骨沉积，比如由于恶性肿瘤或原发性甲状旁腺机能亢进或者骨质疏松症。在另一些病理条件下，可能出现不希望数量的钙沉积，因此会导致如异位钙化、骨关节炎、肾或膀胱结石、动脉粥样硬化和变形性骨炎，这是一种异常高的骨吸收及随后的异常钙沉积共同作用的结果。
阿来屈酯，4-氨基-1-羟基亚丁基-1，1-二磷酸一钠三水合物，是一种治疗骨病，包括骨质疏松症克服骨吸收的药剂，在属于默克(Merck)的美国专利4,922,007和5,019,651中叙述了它作为组合物、用法以及合成方法，同时叙述了其它药物可接受的盐。
有一些情况，比如老年妇女正在服用阿来屈酯治疗骨质疏松症(即骨稀疏)，或者认为有演变为骨质疏松的危险，而且同时经历着吞咽困难。
然而，阿来屈酯目前已以片剂的形式给所有的病人口服。而对于不能很容易吞咽药片的一些病人，唯一可获得的是固体口服剂形是个缺点。再有，这些病人可能在阿来屈酯病人群体中占有很大百分比，因为这种药也打算用给老年病人群体。
在这些场合下，所希望的是用一种改善的口服制剂来有效地治疗使这些老年妇女得到最好的治疗，克服吞咽困难的问题。
发明概述
本发明提出一种方法，通过给吞咽困难的病人施用药物有效量的阿来屈酯口服液体制剂，来治疗和/或预防所述病人骨损失。此液体制剂可以呈糖浆状、水溶液状或水可溶化的阿来屈酯粉末状，它含有缓中剂来调节溶液的pH值，含有络合剂防止形成不溶的阿来屈酯络合物。
本发明的液体口服药物组合物在一种液体药学上可接受的载体比如纯水中含有有药效数量的阿来屈酯；还含有缓冲剂如柠檬酸盐，以保持pH值在2-8，优选在4-6；还含有络合剂如柠檬酸盐或EDTA，以抑制阿来屈酯在水相介质中沉淀。也提供一种含有高浓度蔗糖的上述水溶液，成为一种糖浆，为了市场需要也可以加入矫味剂。
也可提供一种含有粉末供用时溶化的药物组合物，它在药学上可接受的干赋形剂中含有有药效数量的阿来屈酯，同时也有缓冲剂如柠檬酸盐和络合剂存在，所述粉末可溶于水。
本发明的详细说明和优选实施例
呈糖浆、水溶液或用时冲配的粉末水溶液状的阿来屈酯口服溶液有易于服用的优点，对于那些难以吞咽固体口服剂型的病人增加了配合性。用时冲配的粉末还有另一个优点，就是最大限度地减小了占用护士室、药房、医院及库房的空间。这些制剂具有可进行剂量滴定的好处，这将是人们所希望的。
这种方法可以用有骨生成效果量的阿来屈酯来治疗人，特别是绝经后的妇女，需要用这种治疗来抑制骨吸收。在骨折、骨不连合、缺损等情况下，这种需要就局部增加。在系统性骨疾病，如在骨质疏松症、骨关节炎、变形性骨炎、骨软化、骨髓瘤和其它类型的癌、类固醇疗法和与年龄有关的骨本质损失时，这种需要都增大。
在本文中使用的“抑制骨吸收”一词表示治疗和预防骨损失，特别是抑制由于直接或间接的破骨细胞形成或者活性的改变，而使现有的骨骼无论从无机相和/或从有机基质相向外迁移。因此，本文使用的“骨吸收抑制剂”指的是通过直接或间接改变破骨细胞的形成能力或者说活性来防止骨损失的药物，它可以增加病人治疗群体的骨质量。
本文中使用的“成骨效果”指的是能影响成熟骨骼“滚动”的数量，正如在本文中所用的，有成骨效果的剂量也称为“有药效的”。
本文中使用的“治疗”一词，表示(1)给病人提供一定量的阿来屈酯，足能有预防作用地防止虚弱和/或不健康状态发展；和/或(2)给病人提供足够量的阿来屈酯，使得减轻或消除了疾病状态和/或病态的征兆，以及虚弱和/或不健康的状态。
包括了供施用阿来屈酯的本发明药物制剂一般将包括有成骨效果量的阿来屈酯，以促进骨骼生长，此外还有药物可接受的赋形剂。最好用干燥的惰性载体，比如粉末状的糖，包括蔗糖和乳糖、淀粉及其衍生物、纤维素及其衍生物、树胶、脂肪酸及其盐一起制备成组合物。
对于液态制剂，适合的液体赋形剂/载体是纯水和盐溶液。
其它适用的赋形剂和其它的辅助添加剂如下：
溶剂
乙醇
甘油
丙二醇
稳定剂
EDTA(乙二胺四乙酸)
防腐剂
苯甲酸钠
山梨酸
对羟基苯甲酸甲酯
对羟基苯甲酸丙酯
缓冲剂
柠檬酸/柠檬酸钠
酒石酸氢钾
酒石酸氢钠
邻苯二甲酸氢钾
邻苯二甲酸氢钠
磷酸二氢钾
磷酸氢二钠
矫味剂
糖精
乳糖
蔗糖
果糖
山梨糖醇
天冬酰苯丙氨酸甲酯
粘度剂
纤维素衍生物，包括：
羟甲基纤维素
羟丙基纤维素
着色剂
FD&C兰2
FD&C红33
此外，为了将该水液pH值维持在2-8范围，优选在4-6，存在缓冲剂是必须的。
缓冲系统一般是弱酸及其可溶盐的混合物，比如柠檬酸钠/柠檬酸；或者是二价酸的单阳离子或双阳离子盐，比如酒石酸氢钾、酒石酸氢钠、邻苯二甲酸氢钾、邻苯二甲酸氢钠、磷酸二氢钾和磷酸氢二钠。
使用的缓冲剂系统的量取决于：
(1)希望的pH值，以及
(2)阿来屈酯的量
一般说来，使用的缓冲剂的量为缓冲剂与制剂中阿来屈酯的摩尔比为0.5-50∶1，以保持pH值为2-9，一般缓冲剂与阿来屈酯的摩尔比为1-10。
一种有用的缓冲剂是柠檬酸钠/柠檬酸，一般含量为5-50mg/ml的柠檬酸钠至1-15mg/ml的柠檬酸。
还存在有络合剂为的是防止阿来屈酯与可溶的金属离子如Ca、Mg、Fe、Al和Ba形成金属络合物而发生沉淀，它们可能由玻璃容器或橡胶塞子浸出，也可能存在于一般的自来水中。络合剂的作用是与阿来屈酯进行竞争络合的药剂，产生可溶性金属络合物，而阿来屈酯一般形成不溶的金属络合物。络合剂包括作用为缓冲剂/络合剂的柠檬酸缓冲剂或EDTA。当使用EDTA时，其用量为组合物重量的0.005-0.1％，和0.005-2份重量EDTA比1份重阿来屈酯，优选大约为组合物重的0.01％。优选只使用柠檬的盐缓冲剂。
三种阿来屈酯的口服剂形的实施例是：
口服水溶液
将阿来屈酯散药溶于水或适当的助溶剂中达到所需浓度。按需要加入矫味剂、着色剂、粘度剂、防腐剂、稳定剂和缓冲剂。将此溶液装到多剂量或单剂量包装中。
由瓶中直接使用此水溶液。
一般配方
阿来屈酯 0.5-10.0mg
柠檬酸钠 5-50mg
柠檬酸 1-15mg
纯水 适量至1ml
在此制剂中也可按下面专门加入添加剂、助溶剂、矫味剂、着色剂、防腐剂、稳定剂和缓冲剂：
专门配方
阿来屈酯 0.5-10.0mg
柠檬酸钠 5-50mg
柠檬酸 1-15mg
野樱桃(粉)a 10-200mg
FDC红No.33b 0.1-1.0mg
山梨酸 0.05-0.2％
糖精c 1-100mg
丙二醇 5-20％
纯水 适量至1ml
a也可使用野樱桃以外的矫味剂
b也可选择FDC No 33以外的着色剂以配合其它矫味剂
c也可改用蔗糖或天冬氨苯丙氨酸甲酯作为甜味剂
口服糖浆
将阿来屈酯散药加到10-85％的蔗糖溶液中达到所需的浓度。如果需要加入添加剂如甘油、山梨糖醇、矫味剂、着色剂、粘度剂、防腐剂、稳定剂和缓冲剂。将最终的溶液装入多剂量或单剂量包装中。
可直接由瓶中取用糖浆，或加到少量饮用水中以易于吞服。
一般配方
阿来屈酯 0.5-10.0mg
柠檬酸 1-15mg
柠檬酸钠 5-50mg
蔗糖 10-85％
纯水 适量至1ml
也可以专门在制剂中再加入如下的添加剂，比如甘油、山梨糖醇、矫味剂、着色剂、防腐剂、稳定剂和缓冲剂：
专门制剂
阿来/屈酯 0.5-10.0mg
柠檬酸 1-15mg
柠檬酸钠 5-50mg
甘油 5-25％
蔗糖 10-40％
山梨糖醇 10-40％
野樱桃(粉)a 10-200mg
FDC红No.33b 0.1-10mg
山梨酸 0.05-0.2％
纯水 适量至1ml
a也可用野樱桃以外的矫味剂
b也可选用FDC No.33以外的着色剂以与其它矫味剂相匹配
用前冲调的粉末
用一种或多种如下的添加剂与阿来屈酯散药掺和至均匀：矫味剂、着色剂、防腐剂、稳定剂，特别是用缓冲剂。然后把粉状掺和物装入多剂量容器或单剂量包装中。
可将此粉末溶于普通的饮用水中，冲调成阿来屈酯的水溶液。
用于用前冲调的粉末配方
每个单位剂量容器的量d：
阿来屈酯 2-50mg
蔗糖 100-1000mg
柠檬酸钠 25-500mg
柠檬酸 5-500mg
d容器可以是瓶(可向其甲加入水)或药襄袋。另外，可以在多剂量
容器中提供散装药物。
所需的精确剂量将随病人的年龄、身材、性别和状态；要治疾病的种类和严重程度等而变化。因此不能预先就规定精确的剂量，这将由护理医生决定。然而，如下所述，通过动物模型的常规实验可确定适当的用量。一般说来，对于任何口服液体制剂中的阿来屈酯的有效剂量大约为1.5-3000μg/kg体重，优选为约10μg/kg-200μg/kg体重。
本发明的方法和组合物可用来治疗骨折、缺损和由骨质疏松的病理状态导致的疾病、骨关节炎、变形性骨炎、骨质缺乏、骨软化、癌以外的多发骨髓瘤导致的骨损失、其它治疗(如类固醇)的副作用导致的骨损失和与年龄有关的骨体损失等。
Claims (25)
1、在药学上可接受的载体中含有有药效数量的阿来屈酯以及有效量能维持组合物的pH值为2-8范围的缓冲剂和防止阿来屈酯在水溶液中产生沉淀的络合剂的药物组合物。
2、权利要求2的药物组合物是液体。
3、权利要求3的药物组合物，其中所述液体是糖浆。
4、权利要求2的药物组合物，其中所述液体是水溶液。
5、权利要求1的药物组合物，它是一种用前冲调的粉末。
6、权利要求5的可溶于水的药物组合物。
7、权利要求1的药物组合物，其中阿来屈酯的用量为每g组合物0.0005-0.5g。
8、权利要求1的药物组合物，其中所述药学上可接受的赋形剂是纯水。
9、权利要求1的药物组合物，其中所述缓冲剂是柠檬酸钠/柠檬酸、酒石酸氢钾、酒石酸氢钠、磷酸二氢钾和磷酸氢二钠。
10、权利要求1的药物组合物，其中所述缓冲剂的量为缓中剂与阿来屈酯的摩尔比为0.5-50比1。
11、权利要求1的药物组合物，其中所述络合剂为EDTA。
12、权利要求11的药物组合物，其中所述EDTA的用量为每重量份阿来屈酯0.005-2重量份。
13、权利要求1的药物组合物，其中所述pH值在4-6的范围内。
14、权利要求1的药物组合物，它是有如下制剂的糖浆：
阿来屈酯 0.5-10.0mg
柠檬酸 1-15mg
柠檬酸钠 5-50mg
蔗糖 10-85％
纯水 适量至1ml
15、权利要求14的药物组合物，它是有如下制剂的糖浆：
阿来屈酯 0.5-10.0mg
柠檬酸 1-15mg
柠檬酸钠 5-50mg
甘油 5-25％
蔗糖 10-40％
山梨糖醇 10-40％
野樱桃(粉)a 10-200mg
FDC红No.33b 0.1-1.0mg
山梨酸 0.05-0.2％
纯水 适量至1ml
16、权利要求1的药物组合物，它是具有如下制剂的水溶液：
阿来屈酯 0.5-10.0mg
柠檬酸钠 5-50mg
柠檬酸 1-15mg
纯水 适量至1ml
17、权利要求16的组合物，它具有如下的制剂
阿来屈酯 0.5-10.0mg
柠檬酸钠 5-50mg
柠檬酸 1-15mg
野樱桃(粉)a 10-200mg
FDC红No.33b 0.1-1.0mg
山梨酸 0.05-0.2％
糖精c 1-100mg
丙二醇 5-20％
纯水 适量至1ml
18、权利要求1的药物组合物，它是具有如下制剂的用前冲调粉末：
阿来屈酯 2-50mg
蔗糖 100-1000mg
柠檬酸钠 25-500mg
柠檬酸 5-500mg
19、治疗和/或预防难于吞服的对象骨损失的方法，这包括服用有药效数量的含有如权利要求1所定义的阿来屈酯药物组合物的口服液。
20、权利要求19的方法，其中所述对象是人。
21、权利要求19的方法，其中的骨损失与废用导致的骨质疏松症、与年龄、与类固醇治疗、与类风湿病、与变形性骨炎或与癌症都有关系。
22、权利要求19的方法，其中的治疗意味着预防。
23、权利要求19的方法，其中所述液体是糖浆。
24、权利要求19的方法，其中所述液体是水溶液。
25、权利要求19的方法，其中所述液体是由用前冲调粉末调制的水溶液。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/245,289 | 1994-05-17 | ||
| US08/245,289 US5462932A (en) | 1994-05-17 | 1994-05-17 | Oral liquid alendronate formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1148341A true CN1148341A (zh) | 1997-04-23 |
| CN1079672C CN1079672C (zh) | 2002-02-27 |
Family
ID=22926074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95193086A Expired - Fee Related CN1079672C (zh) | 1994-05-17 | 1995-05-12 | 口服阿来屈酯液体制剂 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US5462932A (zh) |
| EP (1) | EP0759757B1 (zh) |
| JP (1) | JP4111536B2 (zh) |
| KR (1) | KR100372966B1 (zh) |
| CN (1) | CN1079672C (zh) |
| AT (1) | ATE222495T1 (zh) |
| AU (1) | AU691634B2 (zh) |
| CA (1) | CA2190148C (zh) |
| CO (1) | CO4600739A1 (zh) |
| CY (1) | CY2336B1 (zh) |
| CZ (1) | CZ285860B6 (zh) |
| DE (1) | DE69527842T2 (zh) |
| DK (1) | DK0759757T3 (zh) |
| DZ (1) | DZ1884A1 (zh) |
| ES (1) | ES2180646T3 (zh) |
| FI (1) | FI118296B (zh) |
| HK (1) | HK1009245A1 (zh) |
| HR (1) | HRP950293B1 (zh) |
| HU (1) | HU220626B1 (zh) |
| IL (1) | IL113651A (zh) |
| MX (1) | MX9605660A (zh) |
| MY (1) | MY112285A (zh) |
| NO (1) | NO310179B1 (zh) |
| NZ (1) | NZ289231A (zh) |
| PL (1) | PL179634B1 (zh) |
| PT (1) | PT759757E (zh) |
| RU (1) | RU2176507C2 (zh) |
| SI (1) | SI0759757T1 (zh) |
| SK (1) | SK281098B6 (zh) |
| TW (1) | TW402501B (zh) |
| UA (1) | UA29505C2 (zh) |
| WO (1) | WO1995031203A1 (zh) |
| YU (1) | YU49354B (zh) |
| ZA (1) | ZA953960B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311835C (zh) * | 2000-01-20 | 2007-04-25 | 弗·哈夫曼-拉罗切有限公司 | 含有双膦酸盐的肠胃外药物组合物 |
| CN103070824A (zh) * | 2013-01-24 | 2013-05-01 | 天津红日药业股份有限公司 | 一种含有伊班膦酸钠的注射液 |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5780455A (en) * | 1994-08-24 | 1998-07-14 | Merck & Co., Inc. | Intravenous alendronate formulations |
| EP0809502A4 (en) * | 1995-02-17 | 2001-12-05 | Merck & Co Inc | PROCESS FOR REDUCING THE RISK OF BONE FRACTURES OTHER THAN VERTEBRAL FRACTURES |
| EP0824341A4 (en) * | 1995-05-12 | 1999-07-07 | Merck & Co Inc | PREVENTING TOOTH LOSS THROUGH ADMINISTRATION OF ALENDRONATE OR ITS SALTS |
| IL118422A0 (en) * | 1995-06-02 | 1996-09-12 | Merck & Co Inc | Use of alendronate for the prevention of osteoporosis |
| US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
| CA2221416A1 (en) * | 1995-06-06 | 1996-12-12 | Merck & Co., Inc. | Bisphosphonate therapy for bone loss associated with rheumatoid arthritis |
| US6100301A (en) * | 1996-02-28 | 2000-08-08 | Pfizer Inc | Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists |
| IL120270A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
| AU723357B2 (en) * | 1996-10-04 | 2000-08-24 | Merck & Co., Inc. | Liquid alendronate formulations |
| US6376477B2 (en) | 1996-11-25 | 2002-04-23 | Merck & Co., Inc. | Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism |
| US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
| US6080779A (en) * | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
| FI104901B (fi) | 1997-10-20 | 2000-04-28 | Leiras Oy | Uudet metyleenibisfosfonihappojohdannaiset |
| GB9802617D0 (en) * | 1998-02-07 | 1998-04-01 | Knoll Ag | Pharmaceutical formulation |
| US6331533B1 (en) | 1998-11-16 | 2001-12-18 | Merck & Co., Inc. | Method for inhibiting dental resorptive lesions |
| US6194469B1 (en) * | 1998-12-11 | 2001-02-27 | Board Of Trustees Operating Michigan State Univeristy | Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids |
| EP1188441A4 (en) * | 1999-06-02 | 2004-01-28 | Procter & Gamble | ORAL PREPARATIONS OF DINATRIUM ETIDRONATE |
| US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| CN1224423C (zh) | 2000-07-17 | 2005-10-26 | 山之内制药株式会社 | 改善口服吸收的医药组合物 |
| ES2243457T3 (es) * | 2001-01-23 | 2005-12-01 | Gador S.A. | Composicion que comprende bifosfonatos para la prevencion y/o tratamiento de trastornos metabolicos de huesos, procedimiento de preparacion de dicha composicion y usos de la misma. |
| US8197561B2 (en) | 2001-10-10 | 2012-06-12 | River Basin Energy, Inc. | Process for drying coal |
| US7537622B2 (en) * | 2001-10-10 | 2009-05-26 | Fmi Newcoal, Inc. | Process for drying coal |
| US7695535B2 (en) | 2001-10-10 | 2010-04-13 | River Basin Energy, Inc. | Process for in-situ passivation of partially-dried coal |
| US20030139378A1 (en) * | 2001-12-13 | 2003-07-24 | Daifotis Anastasia G. | Liquid bisphosphonate formulations for bone disorders |
| WO2003055496A1 (en) * | 2001-12-21 | 2003-07-10 | The Procter & Gamble Company | Method for the treatment of bone disorders |
| KR20120065435A (ko) * | 2002-05-10 | 2012-06-20 | 에프. 호프만-라 로슈 아게 | 골다공증 치료 및 예방용 비스포스폰산 |
| ITTO20020406A1 (it) * | 2002-05-13 | 2003-11-13 | Chiesi Farma Spa | Formulazioni di bisfosfonati ad uso iniettabile. |
| US7041309B2 (en) * | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
| GR1004331B (el) * | 2002-10-07 | 2003-09-05 | Verisfield (Uk) Ltd | Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος |
| BR0309691A (pt) * | 2002-12-20 | 2005-08-02 | Hoffmann La Roche | Formulação de ibandronato em alta dose |
| US20050101605A1 (en) * | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
| KR20080083068A (ko) * | 2004-05-24 | 2008-09-12 | 더 프록터 앤드 갬블 캄파니 | 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태 |
| US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US7645460B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| WO2006009912A1 (en) * | 2004-06-23 | 2006-01-26 | Merck & Co., Inc. | Estrogen receptor modulators |
| EP1796683A1 (en) * | 2004-07-15 | 2007-06-20 | Nanobac Life Sciences | Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses |
| WO2006020009A1 (en) * | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Solid oral dosage form of a bisphosphonate containing a chelating agent |
| US8012949B2 (en) * | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
| US7358361B2 (en) * | 2004-10-08 | 2008-04-15 | The Board Of Trustees Of The University Of Illinois | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
| CA2646334A1 (en) * | 2006-03-17 | 2007-09-27 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
| DK1894557T3 (da) * | 2006-09-04 | 2011-05-30 | Gador Sa | Flydende sammensætning til behandling og/eller forebyggelse af forskellige metaboliske knoglesygdomme, anvendelse heraf og fremgangsmåde til fremstilling heraf |
| US20080132471A1 (en) * | 2006-11-21 | 2008-06-05 | Teikoku Pharma Usa, Inc. | Bisphosphonate inhalant formulations and methods for using the same |
| US8974801B2 (en) * | 2006-12-21 | 2015-03-10 | Amphastar Pharmaceuticals Inc. | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
| US20090170815A1 (en) * | 2007-12-28 | 2009-07-02 | Roxane Laboratories Incorporated. | Alendronate oral liquid formulations |
| US20090197837A1 (en) * | 2008-02-05 | 2009-08-06 | Desai Vivek S | Alendronate formulations, method of making and method of use thereof |
| US20100034752A1 (en) * | 2008-08-11 | 2010-02-11 | Toru Hibi | Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same |
| US9057037B2 (en) | 2010-04-20 | 2015-06-16 | River Basin Energy, Inc. | Post torrefaction biomass pelletization |
| US8956426B2 (en) | 2010-04-20 | 2015-02-17 | River Basin Energy, Inc. | Method of drying biomass |
| US9889225B2 (en) * | 2010-08-20 | 2018-02-13 | Kaohsiung Medical University | Method for bone formation by administering poly(lactic-co-glycolic acid) cross-linked alendronate |
| BR112013010476B1 (pt) | 2010-12-06 | 2021-07-06 | Effrx Pharmaceuticals Sa | formulações efervescentes estáveis de bisfosfonato com características de solubilização rápida |
| ES2750246T3 (es) * | 2013-10-08 | 2020-03-25 | Innopharma Inc | Formulaciones liquidas orales de aprepitant |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1187828B (it) * | 1985-05-24 | 1987-12-23 | Gentili Ist Spa | Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi |
| GB8618259D0 (en) * | 1986-07-25 | 1986-09-03 | Leo Pharm Prod Ltd | Pharmaceutical compositions |
| DE3822650A1 (de) * | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| FI83421C (fi) * | 1989-06-21 | 1991-07-10 | Huhtamaeki Oy | Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat. |
| US5227506A (en) * | 1989-09-06 | 1993-07-13 | Merck & Co., Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
| US5356887A (en) * | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
| CA2035179C (en) * | 1990-01-31 | 2001-08-14 | Gerald S. Brenner | Pharmaceutical compositions containing insoluble salts of bisphosphonic acids |
| US5019651A (en) * | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| FR2703590B1 (fr) * | 1993-04-05 | 1995-06-30 | Sanofi Elf | Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse . |
-
1994
- 1994-05-17 US US08/245,289 patent/US5462932A/en not_active Expired - Lifetime
-
1995
- 1995-05-08 IL IL11365195A patent/IL113651A/xx not_active IP Right Cessation
- 1995-05-09 TW TW084104572A patent/TW402501B/zh not_active IP Right Cessation
- 1995-05-11 MY MYPI95001236A patent/MY112285A/en unknown
- 1995-05-12 EP EP95924570A patent/EP0759757B1/en not_active Expired - Lifetime
- 1995-05-12 SK SK1477-96A patent/SK281098B6/sk unknown
- 1995-05-12 RU RU96123917/14A patent/RU2176507C2/ru not_active IP Right Cessation
- 1995-05-12 HU HU9603162A patent/HU220626B1/hu not_active IP Right Cessation
- 1995-05-12 DK DK95924570T patent/DK0759757T3/da active
- 1995-05-12 AT AT95924570T patent/ATE222495T1/de active
- 1995-05-12 JP JP52977395A patent/JP4111536B2/ja not_active Expired - Fee Related
- 1995-05-12 CN CN95193086A patent/CN1079672C/zh not_active Expired - Fee Related
- 1995-05-12 CA CA002190148A patent/CA2190148C/en not_active Expired - Fee Related
- 1995-05-12 AU AU29010/95A patent/AU691634B2/en not_active Expired
- 1995-05-12 WO PCT/US1995/005926 patent/WO1995031203A1/en active IP Right Grant
- 1995-05-12 MX MX9605660A patent/MX9605660A/es unknown
- 1995-05-12 PT PT95924570T patent/PT759757E/pt unknown
- 1995-05-12 SI SI9530610T patent/SI0759757T1/xx unknown
- 1995-05-12 PL PL95320614A patent/PL179634B1/pl not_active IP Right Cessation
- 1995-05-12 KR KR1019960706447A patent/KR100372966B1/ko not_active IP Right Cessation
- 1995-05-12 NZ NZ289231A patent/NZ289231A/en unknown
- 1995-05-12 ES ES95924570T patent/ES2180646T3/es not_active Expired - Lifetime
- 1995-05-12 CZ CZ963367A patent/CZ285860B6/cs not_active IP Right Cessation
- 1995-05-12 UA UA96124659A patent/UA29505C2/uk unknown
- 1995-05-12 DE DE69527842T patent/DE69527842T2/de not_active Expired - Lifetime
- 1995-05-16 DZ DZ950055A patent/DZ1884A1/fr active
- 1995-05-16 HR HR950293A patent/HRP950293B1/xx not_active IP Right Cessation
- 1995-05-16 CO CO95020682A patent/CO4600739A1/es unknown
- 1995-05-16 ZA ZA953960A patent/ZA953960B/xx unknown
- 1995-05-17 YU YU31795A patent/YU49354B/sh unknown
-
1996
- 1996-11-15 FI FI964593A patent/FI118296B/fi not_active IP Right Cessation
- 1996-11-15 NO NO19964864A patent/NO310179B1/no not_active IP Right Cessation
-
1998
- 1998-08-12 HK HK98109860A patent/HK1009245A1/xx not_active IP Right Cessation
-
2003
- 2003-03-03 CY CY0300019A patent/CY2336B1/xx unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311835C (zh) * | 2000-01-20 | 2007-04-25 | 弗·哈夫曼-拉罗切有限公司 | 含有双膦酸盐的肠胃外药物组合物 |
| CN103070824A (zh) * | 2013-01-24 | 2013-05-01 | 天津红日药业股份有限公司 | 一种含有伊班膦酸钠的注射液 |
| CN103070824B (zh) * | 2013-01-24 | 2014-07-16 | 天津红日药业股份有限公司 | 一种含有伊班膦酸钠的注射液 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1079672C (zh) | 口服阿来屈酯液体制剂 | |
| EP1594499A1 (en) | Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer | |
| JP2004075690A (ja) | 静脈内注入用アレンドロナート組成物 | |
| CN109906079A (zh) | 用于质子泵抑制剂混悬剂的组合物和方法 | |
| JP2008056567A (ja) | 胃腸疾患の治療又は予防のための医薬 | |
| CN1228708A (zh) | 经口给药用含肽药物组合物 | |
| CN1238691A (zh) | 液体阿仑膦酸盐制剂 | |
| US20200016101A1 (en) | Pharmaceutical quality strontium l-lactate | |
| WO2019134534A1 (zh) | 一种e-10-羟基-2-癸烯酸在制备防治骨质疏松症的药品或保健品中的应用 | |
| CN1151793C (zh) | 多发性骨髓瘤的骨病变治疗用医药组合物 | |
| BRPI0615770A2 (pt) | formulação de bisfosfonato | |
| JP4652689B2 (ja) | 骨再生を促進するカルモジュリンの使用 | |
| US20160310578A1 (en) | Method of accelerating osteogenesis | |
| CN1060336C (zh) | 一种防治钙质缺损的药物及其制备方法 | |
| JP6771274B2 (ja) | 内服用組成物 | |
| US20240261351A1 (en) | Compositions and methods for the treatment of bone and joint diseases | |
| RU2783692C1 (ru) | Способ периоперационного ведения пациентов с использованием нутритивной поддержки в сипинговой форме в сочетании с инъекциями глюкокортикоидов при хирургических стоматологических вмешательствах | |
| AU5778801A (en) | Improvements in effervescent tablet manufacture | |
| KR20200083971A (ko) | 칼슘 보충용 조성물 | |
| CN114366764A (zh) | 一种提高人体免疫力，预防和/或治疗骨关节炎的组合物 | |
| CN1241929C (zh) | 氨基葡萄糖双磷酸盐及其合成方法并该盐用于治疗骨病药剂的制备 | |
| RU2377974C2 (ru) | Наружное средство для лечения заболеваний суставов и мягких тканей | |
| CN1475218A (zh) | 一种由双磷酸盐和氨基葡萄糖盐组成的药用制剂及其用途 | |
| JP2010159216A (ja) | 鎮痛剤及び鎮痛システム | |
| US20160339063A1 (en) | Composition for preventing and healing compromised bone and a method of making same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |